Deccan Health Care Limited has announced strong financial results for the quarter and nine months ended December 31, 2025, demonstrating robust growth across key performance metrics. The company's sustained operational momentum and strategic execution have translated into significant improvements in revenue, profitability, and earnings per share.

Quarterly Financial Performance

The company's standalone performance for Q3FY26 showed remarkable improvement across all major financial parameters:

The exceptional growth in profitability metrics reflects the company's focus on operational efficiency, cost optimization initiatives, and improved production efficiencies. The revenue expansion was driven by market expansion efforts and stronger contribution from higher-margin product categories.

Nine-Month Performance Highlights

For the nine-month period ended December 31, 2025, Deccan Health Care maintained strong momentum with consistent growth across financial metrics:

The nine-month results demonstrate the company's ability to sustain growth momentum throughout the financial year, with revenue growth of 27% and nearly doubling of profit after tax.

Strategic Developments and Market Expansion

Deccan Health Care achieved significant milestones in its international expansion strategy during the quarter. The company successfully completed its UAE product registration process, marking a crucial step in its export readiness initiatives. The first export consignment is expected to be shipped in the first quarter of the next financial year, opening new revenue streams for the company.

Key strategic priorities during the quarter included:

• Expansion into new markets while deepening penetration in existing geographies
• Cost optimization initiatives across operations
• Strengthening presence in higher-margin R&D-driven product categories
• Improving production efficiency and yield across manufacturing facilities

Product Portfolio and Innovation

The company's nutraceutical weight wellness lifestyle range, launched in the previous quarter, has received encouraging market response and growing customer traction. This positive reception reinforces confidence in the long-term potential of this product category and demonstrates the company's ability to innovate and capture emerging market opportunities.

Consolidated Performance

On a consolidated basis, the company showed steady quarter-on-quarter improvement with PAT of ₹100.25 lakhs in Q3FY26, representing a 10% increase from ₹91.40 lakhs in Q2FY26. Basic EPS on consolidated basis reached ₹0.41, up 11% from ₹0.37 in the previous quarter.

For the nine-month consolidated performance:

The results reflect a company that is strengthening its profitability profile while maintaining disciplined execution, export readiness, and innovation-led expansion. Deccan Health Care Limited remains focused on sustainable long-term value creation for all stakeholders through structured consolidation and disciplined growth strategies.

Deccan health care Limited has announced the immediate resignation of its Company Secretary and Compliance Officer, Mr. Ronak Darji, effective from the close of business hours on December 01, 2025. The company communicated this development to BSE Limited on December 03, 2025, under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Leadership Transition Details

Following Darji's departure, the company has appointed Ms. Mohita Gupta, Chief Operating Officer (COO), as the designated compliance officer. The transition was formalized through official communication to the stock exchange, ensuring regulatory compliance requirements are maintained.

Resignation Circumstances

According to Darji's resignation letter dated December 01, 2025, he cited financial hardship due to pending salary payments as the primary reason for his immediate departure. He specifically mentioned that his salary for October 2025 remained unpaid, and November 2025 salary had become due. Under the terms of his appointment, he was permitted to terminate employment by paying salary in lieu of the notice period.

Company's Response and Concerns

The company's management, through COO Mohita Gupta, expressed concerns about the abrupt nature of the resignation and highlighted several operational issues. The response letter detailed specific concerns about Darji's recent performance and compliance matters.

Performance and Compliance Issues Identified

The company's response outlined several areas of concern during Darji's tenure:

• Delays in statutory filings and incomplete compliance submissions
• Missed deadlines and lack of responsiveness on regulatory matters
• Inconsistencies and overall delays in meeting statutory deadlines
• Pending compliance irregularities that required attention

Resignation Acceptance Terms

The company accepted Darji's resignation with immediate effect, subject to specific conditions outlined in their response. These conditions ensure proper transition and regulatory compliance.

Regulatory Compliance and Accountability

The company emphasized that as Key Managerial Personnel (KMP) under Section 203 of the Companies Act, 2013, Darji remains accountable for any compliance irregularities identified during his service period. This statutory designation ensures continuing responsibility for any issues arising from his tenure, including potential fines and penalties.

Corporate Information

Deccan Health Care Limited operates from its registered office in Hyderabad, Telangana, with an innovation hub and manufacturing facility in Uttarakhand. The company specializes in healthcare solutions and maintains its listing on BSE Limited under stock code 542248. The organization continues its operations under the leadership of the existing management team while ensuring regulatory compliance through the newly designated compliance officer.